SingHealth DukeNUS ACADEMIC MEDICAL CENTRE
PATHOLOGY

SingHealth DukeNUS ACADEMIC MEDICAL CENTRE
National Cancer Research Institute Singapore

RESEARCH GRAND ROUND

New Insights from Old Targets – An Updated View of Endocrine Therapies for the Treatment of Breast and Prostate Cancers

Duke-NUS Amphitheatre

9 July 2026, Thursday

12.00 – 1.00 pm
(Lunch will be served at 11.30am)

HOSTED BY:
A/Prof Jabed Iqbal
Academic Vice Chair, Research, PATH ACP
Senior Consultant, Dept of Anatomical Pathology, Singapore General Hospital

for.sg

REGISTRATION IS FREE!

Please scan QR code to register by **3 July 2026** to facilitate catering

ABOUT THE TALK

Since the introduction of oophorectomy in 1895 as a treatment for breast cancer in premenopausal women, and the demonstration in 1941 that surgical castration reduces the growth and progression of prostate cancer, pharmacological approaches targeting estrogen and androgen signaling have been the cornerstone of interventions used for the treatment of these hormone-driven cancers. The goal of these endocrine therapies has been to maximally inhibit signaling pathways downstream of the estrogen and androgen receptors in cancer cells. Although highly successful, the development of resistance hampers long term remission in a subset of patients, highlighting a significant knowledge gap in endocrine therapy. Research from our laboratory exploring the cancer cell-extrinsic actions of estrogens has uncovered important immunomodulatory activities of estrogens in the tumor microenvironment and identified approaches to improve therapeutic responses. Applying insights from our discovery of the non-linear pharmacology of androgens we have also identified new strategies to treat prostate cancer.

ABOUT THE SPEAKER

Dr. Ching-Yi Chang is an Associate Research Professor in the Department of Pharmacology and Cancer Biology at Duke University. She serves as a senior investigator in Dr. Donald McDonnell's research group, which is internationally recognized for its seminal contributions to nuclear and steroid hormone receptor biology and the development of therapies for breast and prostate cancers. Notable is this group's discovery of the utility of elacestrant (Orserdu, FDA approved January 2023) and lasofoxifene (currently in Phase 3 clinical trials) for the treatment of metastatic breast cancer. Her research focuses on receptor biology and hormone signaling, with an emphasis on endocrine therapy resistance, cancer metabolism, tumor immunology, and the translation of fundamental discoveries into novel therapeutic strategies.

A/Prof Chang Ching-yi
Duke University

For enquiries, please email ong.yoong.hun@sgh.com.sg (PATH ACP) or jayden.c@duke-nus.edu.sg (NCRIS).
CME accreditation will be applied for.

Please note that your photograph may be taken during this event for use in promotional brochures, event publicity and other related purposes by SingHealth, its related corporations and its service providers.